Comments Submitted to the FDA Regarding Reauthorization of the Medical Device User Fee Amendments for Fiscal Years 2023 Through 2027 (MDUFA V) April 21, 2022
Letters, Testimony & Filings Testimony at the FDA’s Public Meeting Regarding Medical Device User Fee Amendments for Fiscal Years 2023 Through 2027 April 19, 2022
Press Releases CPSC Action Insufficient to Stem the Tide of Fatalities Caused by Adult Portable Bed Rails March 16, 2022
Letters, Testimony & Filings Letter to Congress Calling for Amendments to S. 3799, the PREVENT Pandemics Act March 14, 2022
Testimony Before the FDA’s Neurological Devices Advisory Committee Meeting Regarding BrainGate LTD’s Ischemic Stroke System December 10, 2021
Forum Article Published in Drug and Therapeutics Bulletin: Mandatory Disclosure of All Pharmaceutical and Medical Device Companies’ Payments to Healthcare Providers: Learning From the USA December 7, 2021
Letter to President Biden Opposing the President and CEO of the Biotechnology Innovation Organization as a Candidate for FDA Commissioner October 12, 2021
Letter to the FDA Urging the Agency Not to Grant 510(k) Premarket Clearance for the TriGUARD 3 Cerebral Embolic Protection Device August 17, 2021